Key takeaways
Zinbryta (daclizumab) and Tysabri (natalizumab) are both monoclonal antibodies used to treat relapsing forms of multiple sclerosis (MS). Zinbryta is a monoclonal antibody that helped lower inflammationin the brain. However, it was discontinued in the United States due to safety concerns, including liver injury and immune-related problems. In contrast, Tysabri is still available that binds to integrin, a protein, to help reduce inflammation in the nerves and gut. Tysabri is also approved for treating Crohn's disease (CD) that hasn't responded well to other treatments. It is administered as a monthly IV infusion and requires enrollment in the TOUCH Prescribing Program to monitor for serious side effects like infections and liver problems. Tysabri can cause progressive multifocal leukoencephalopathy (PML), a severe brain infection. It (natalizumab) is only available as a brand-name medication, which can be expensive, however there is a biosimilar available that may be more affordable.
